Tirzepatide (Zepbound) Approved for Chronic Weight Management

Nov 08, 2023, 11:30 PM
Headliner
Share
Subscribe
In this episode, hosts discuss the FDA's approval of tirzeptiade (Zepbound) as an adjunct to lifestyle modification for the chronic weight management in people with overweight or obesity.
Share
Subscribe
Next
SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
Top episodes
Orforglipron, Retatrutide, and Other GLP-1 Updates
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Key Updates in ADA Standards of Care—2024
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives